Pharmaceutical organizations have invested heavily in digital infrastructure for managing promotional content and Medical, Legal, and Regulatory review.
For many organizations, Veeva Vault PromoMats plays an important role in that infrastructure.
The emergence of agentic AI introduces a new question:
Does a pharmaceutical company need to replace its existing MLR platform to take advantage of AI?
Not necessarily.
A different model is emerging in which agentic AI operates as an intelligence layer alongside established enterprise systems.
Systems of Record vs. Systems of Intelligence
Traditional enterprise platforms are extremely valuable for managing records, workflows, permissions, approvals, and content.
Agentic AI solves a different problem.
It can analyze the information contained within those systems.
For MLR, that can include identifying claims, analyzing supporting evidence, surfacing regulatory considerations, and helping reviewers investigate potential issues.
This creates an important distinction between the system of record and the system of intelligence.
Where ERMA Fits
ERMA Systems is designed to operate either as a standalone MLR environment or alongside existing pharmaceutical technology infrastructure.
For organizations using Veeva Vault PromoMats, the architectural objective is straightforward:
Allow the organization to maintain its established content and workflow environment while introducing ERMA's AI-powered compliance intelligence.
ERMA's integration architecture has been designed around available API frameworks so relevant content and workflow information can ultimately move between systems based on customer configuration and permissions.
What Agentic AI Adds
Once content becomes available to an AI intelligence layer, specialized agents can begin performing work around it.
ERMA can support capabilities including:
- AI claims detection
- Reference analysis and assignment
- Regulatory intelligence
- Content and version comparison
- Compliance-focused analysis
- Review preparation
The objective is not simply another place to store promotional materials.
It is to make the information surrounding those materials more intelligent.
Why This Architecture Matters
Large pharmaceutical organizations rarely replace enterprise systems overnight.
They have established processes, validated environments, integrations, training programs, and governance requirements.
An intelligence-layer strategy creates another path.
Organizations can maintain existing infrastructure while selectively introducing agentic capabilities into processes where AI can provide measurable value.
The Future May Be an Ecosystem
The next generation of pharmaceutical technology may not be defined by a single platform attempting to perform every function.
Instead, organizations may combine enterprise systems of record with specialized AI systems capable of providing deeper intelligence.
For MLR teams, that means the conversation around AI should extend beyond workflow automation.
The bigger opportunity is creating a technology ecosystem where existing infrastructure manages the process while AI increasingly helps understand the science, evidence, claims, and regulatory considerations within it.
That's the role ERMA Systems is building for the future of life sciences compliance.